 Today I have the pleasure speaking with Thomas Smeak from Hema Stemix. How are you today, Thomas? Very well, Tracy. How are you? Thomas, you're involved in a very exciting sector stem cell research or stem cells in general. So we've got, what, 91 patents? Did I read that right? Yes, that is right. 91 patents, including a patent on the automation of production, which enables us to scale the business. So for anybody my age or older or maybe even younger, age management and, of course, helping people repair from injuries, is this correct? Do I understand this or am I just guessing? Yeah, it's an angiogenic cell precursor that, in a phrase, is the fountain of youth. If you want to think of Hema Stemix in one phrase, it is the fountain of youth company. So Hema Stemix, fountain of youth. Some people out there are going, OK, I haven't heard of this company. This is definitely a tune that is resonating with us. I was explaining to you, we were talking about this earlier, because we're both, of course, investors. And I said, you know, there's a lot of companies out there competing for investors' attention. You're already getting ours. We're talking about fountain of youth. But why Hema Stemix and why now? The concept of fountain of youth is embodied in what an angiogenic cell precursor does. It essentially treats ischemia, where that is, and that ischemia being lack of circulation, in the body where it occurs. We have treated some 500 patients on a compassionate basis for ischemia that occurs in the heart. And that's described as angina or ischemia that happens in the arteries, dilated cardiomyopathy and ischemic cardiomyopathy. Or ischemia that happens in the leg, foot and toes of diabetics, where they end up getting ulcerating wounds that will not heal and turn gangrenous. That being critical limb ischemia. And we're now in a phase two clinical trial that is proving scientifically what we've seen in the clinic. Namely that seven or eight of 10 patients are able to save their limbs from otherwise certain amputation. So I was looking, I was doing some research before we started this phone call. You know, I mentioned to you, I really love your name. You've been putting out news regularly a couple of times a month here since the new year. I see about a dozen news releases. But all of that aside, you're saying a lot of things that sound interesting. But I'm going to hit you hard here, Thomas. I'm an investor. How do we make money with this fountain of youth? So the company treats ischemia at a cost of $25,000 a treatment. And we think that through automation, we'll be able to scale the business to go from 20 patient batches a month to 100 and then exponentially from there to 1000 batches a month and so on. Obviously, at 1000 batches a month, we're generating 25 million in revenue. So there are a million patients a year that are losing their limb to amputation in North America. And that requires us to exponentially produce ACP at a rate of a million batches a year. A million batches at 25,000 is 25 billion. And that's a reoccurring annual market. So you've just answered the questions that I know a lot of us out here were trying to calculate and we're going to ask you next. So thank you for that. So how fast we've been able to ramp this up and get the approvals that are required to really get competitive in this marketplace? Or are you the only competitor in town? So we are at a phase two clinical trial in Asia and in North America. In fact, in Japan, South Korea, you can treat with adequate phase two results. You can treat under the right to trial legislation in the US. And so we are in this actually just announced a four million dollar financing. We're going to take approximately a million of that and put it into the re-establishment of production. And that will enable us to start generating revenue. Start generating revenue this year? In approximately 12 months. And approximately 12 months. OK, fantastic. Thomas, we are so excited to hear a little bit more about this. So in addition to the ischemia, did I pronounce that properly? Yes, it sounds to me like you might have other markets you can go to in as well. Can you talk about those? Yes. So the peripheral or chill disease, there's 200 million diabetics suffering from peripheral or chill disease. You know, one in three people are suffering from cardiovascular diseases. And hemostemics, ACP product actually treats that ischemia again, where it is occurring in the body, whether it's the heart, the lungs or the or the legs. Thomas, I know there's a lot of everyone's looking at the Canadian biotech sector. This sounds arguably too good to be true. So what we're going to do an investor in tells, we're going to invite you on monthly. I'm going to have investors send me questions. We're going to ask you questions more about this and and and we would like to have you on regularly if you're open to that. Are you? That would be fantastic. Yes. Thank you, Tracy. All right, Thomas, thank you for joining us today and everybody out there. Make sure you're watching hemostemics. Thanks very much.